WO1996003147A1 - Synthesis of chemical gels from polyelectrolyte polysaccharides by gamma-irradiation - Google Patents

Synthesis of chemical gels from polyelectrolyte polysaccharides by gamma-irradiation Download PDF

Info

Publication number
WO1996003147A1
WO1996003147A1 PCT/US1995/007224 US9507224W WO9603147A1 WO 1996003147 A1 WO1996003147 A1 WO 1996003147A1 US 9507224 W US9507224 W US 9507224W WO 9603147 A1 WO9603147 A1 WO 9603147A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
irradiation
polysaccharide
gamma
hydrogels
Prior art date
Application number
PCT/US1995/007224
Other languages
French (fr)
Inventor
Kinam Park
Annamaria Paparella
Luca Benedetti
Original Assignee
Fidia Advanced Biopolymers, S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Advanced Biopolymers, S.R.L. filed Critical Fidia Advanced Biopolymers, S.R.L.
Priority to AU28187/95A priority Critical patent/AU2818795A/en
Publication of WO1996003147A1 publication Critical patent/WO1996003147A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/042Gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/732Starch; Amylose; Amylopectin; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28Polysaccharides or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/042Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

Definitions

  • the present invention is directed to a method for the synthesis of chemical gels or hydrogels by gamma- irradiation, starting with polyelectrolyte polysaccharides, such as alginic acid, hyaluronic acid and the esters thereof.
  • the present invention is also directed to the chemical gel or hydrogel produced by this method. Gels synthesized by the described method can be used as slow release systems for drugs. FIELD OF THE INVENTION
  • Gels for pharmaceutical use are generally prepared from polymers by chemical means, such as by cross- linking the polymeric chain.
  • a method for synthesizing biocompatible chemical gels or hydrogels which includes reacting polyelectrolyte polysaccharides with a functionalizing agent in order to introduce double bonds into the structure so as to produce functionalized polyelectrolyte polysaccharides; and subjecting the functionalized polyelectrolyte polysaccharides to gamma- irradiation in order to produce the chemical gels.
  • Figures 1, 2 and 3 show the conditions needed for the formation of gels from alginic acid, hyaluronic acid, and the 25% benzyl ester of hyaluronic acid.
  • Figure 1 is a graph showing the effect of the duration of gamma-irradiation and the effect of the concentration of sodium alginate on gel formation.
  • Figure 2 is a graph showing the effect of the duration of gamma-irradiation and of the concentration of hyaluronic acid on gel formation.
  • Figure 3 is a graph showing the affect of the duration of gamma-irradiation and of the concentration of the 25% benzyl ester of hyaluronic acid (HA-25) on gel formation.
  • Figure 4 is a schematic diagram which shows in the upper portion a representation of the functionalization reaction between a polysaccharide (PS) with glycidyl acrylate; and in the lower portion a representation of the formation of one type of crosslinkage between two functionalized polysaccharides that are subjected to gamma-irradiation.
  • PS polysaccharide
  • the present invention has made it possible to synthesize chemical gels or hydrogels from polyelectrolyte polysaccharides using gamma-irradiation.
  • Polyelectrolyte polysaccharides are natural polymeric substances which contain ionic constituents.
  • Polyelectrolyte polysaccharides tend to swell when placed in water in order to minimize the repulsion between like positive or negative charges of the ionic constituents. These properties result in the so-called "polyelectrolyte" effect.
  • polyelectrolyte polysaccharides include alginic acid, alginates, hyaluronic acid, hyaluronic acid esters including benzyl esters, polysialic acid, gellan, xanthane, welan, pectin, and glycosaminoglycans including condroitin sulphates, heparin sulphates, etc., as well as derivatives of these polysaccharides.
  • These polyelectrolyte polysaccharides contrast with other natural polymeric substances, such as dextran and gelatin, which do not exhibit similar electrolytic properties and do not have the same chemical structure containing such ionic constituents.
  • the method of the present invention provides for acidification of solutions of polyelectrolyte polysaccharides which have been functionalized with glycidyl acrylate, within a suitable pH range. Following irradiation, the acidified solutions give rise to the formation of gels at lower concentrations of polymers and for shorter irradiation times.
  • the functionalization reaction for introducing double bonds into the polyelectrolyte polysaccharides involved the use of an appropriate functionalizing agent, such as glycidyl acrylate.
  • an appropriate functionalizing agent such as glycidyl acrylate.
  • the upper reaction illustrates the reaction between glycidyl acrylate and the hydroxy group of a polyelectrolyte polysaccharides (i.e. "PS") .
  • PS polyelectrolyte polysaccharides
  • Figure 4 shows in the lower reaction scheme a simplified illustration of the functionalized polyelectrolyte polysaccharide containing a number "n" of double bonds which is subjected to gamma-irradiation in order to form one type of a crosslinked structure after the opening of the double bonds and the formation of radicals.
  • the resulting crosslinks constitute aliphatic chains of a given length and result in the formation of gels having a three- dimensional structure which exhibits certain strength and resistance properties.
  • the resulting gels may be defined as polyelectrolytes having unique properties including a significant dependence on the pH and a significant dependence on the ionic strength of the aqueous medium in which the resulting gels are allowed to swell .
  • the method of synthesis of gels is conducted using solutions of polyelectrolyte polysaccharides at various concentrations.
  • concentration range of 1-3% w/v may be used for alginic acid, hyaluronic acid and benzyl esters of hyaluronic acid with 25% esterification.
  • polyelectrolyte polysaccharides may be functionalized using different quantities of an appropriate functionalizing agent such as glycidyl acrylate, for example in the range of 0.8-1.3 ml/1 g of polyelectrolyte polysaccharide.
  • an appropriate functionalizing agent such as glycidyl acrylate
  • Acidification of the polyelectrolyte polysaccharides in solution may be performed by the addition of a suitable acid, such as citric acid, hydrochloric acid or acetic acid, preferably without significantly altering the initial concentration of the polyelectrolyte polysaccharide.
  • the polyelectrolyte polysaccharides are acidified in a pH range of from 1 to 6, more preferably a pH range of from 1 to 5, still more preferably of from 3 to 6, and most preferably between 2.5 and 3.5, before being subjected to gamma- irradiation.
  • the acidification of the polyelectrolyte polysaccharide solution makes it possible to obtain gel formation at lower concentrations of the polymer and lower doses of irradiation.
  • the polyelectrolyte polysaccharides are subjected to gamma-irradiation at a preferable dose range of from at least 0.01 to 0.5 Mrad, more preferably from 0.05 to 0.5 Mrad, and most preferably from about 0.0606 to 0.485 Mrad.
  • the time periods during which the polyelectrolyte polysaccharides are subjected to gamma-irradiation is generally in the range of from 1 to 8 hours.
  • the gamma-irradiation dose may be 0.0606 Mrad/h for time intervals varying from about 1 to 8 hours.
  • the polyelectrolyte polysaccharides may also be subjected to direct gamma-irradiation before acidification. It is preferable not to increase the irradiation dose above 0.5 Mrad because of the degradation effects that may occur. For example, the swelling ratio (Q) of the gels increases at doses of gamma-irradiation at 0.485 Mrad which suggests some degradation of the crosslinked structure of the gels. Also, if the produced gels are intended to be used in "drug delivery" systems, the use of lower doses of irradiation minimizes the possibility of damaging the biological activity of the active drug or principle incorporated into the gel.
  • the gels thus obtained swell when placed in water.
  • Some of the synthesized gels described below were characterized by calculating their equilibrium swelling ratio (Q) , based on the weight of the dry gel and that which has swollen to equilibrium (W. S. W. Shalaby, K. Park , Pharm . Res . , 7 , 816 - 823 , 1990 ) .
  • Figures 1, 2 and 3 show the conditions needed for the formation of gels, in the case of alginic acid, hyaluronic acid and the 25% benzyl ester of hyaluronic acid (HA-25) , respectively.
  • the lines in Figures 1-3 indicate the minimum concentration needed for the formation of three-dimensional gels at set gamma-- irradiation times.
  • the acidification of such solutions before irradiation therefore, allows the formation of gels with lower polymer concentrations and shorter irradiation times, thus avoiding possible degradation of the polymer.
  • the gels synthesized according to the methods of the present invention can be used in the fields of medicine, health care, surgery and cosmetics, as well as in reconstructive and cosmetic surgery.
  • gels in the form of films or membranes can be used in various medical fields, such as in ophthalmology, dermatology, otorhinolaryngology and neurology, as tissue substitutes or organ coatings, as well as in tissue and organ transplants.
  • the gels can generally be used as a biocompatible material in cell cultures in three-dimensional systems, as well as in the form of fibers or threads for surgical suture, or in the form of gauzes for wound dressings.
  • the gels of the present invention preferably include crosslinkage throughout the entire product such that all the polyelectrolyte molecules crosslink to form a single chemical entity.
  • Another important use for the compounds obtained by the method of synthesis of the present invention is as a controlled release system of one or more active principles, such as proteins, growth factors, enzymes, drugs or biologically active substances for oral, topical, s.c, i.m. or i.v. administration. Indeed, according to the dose of gamma-irradiation used, it is possible to obtain three-dimensional gels for use as drug release systems for topical or oral administration, or viscoelastic solutions in order to administer by the subcutaneous, intramuscular or intravenous routes.
  • active principles such as proteins, growth factors, enzymes, drugs or biologically active substances for oral, topical, s.c, i.m. or i.v. administration.
  • biocompatible characteristics of the chemical gels or hydrogels of the present invention allows for their employment in potential and actual biomedical applications similar to those of conventional hydrogels, such as coatings for sutures, catheters, IUD's, blood detoxicants, electrode Sensors, vascular grafts, electrophoresis cells and cell culture substrates; homogeneous-type materials including electrophoresis gels, contact lenses, artificial corneas, vitreous humor replacements, estrous-inducers, breast or other soft tissue substitutes, burn dressings, bone ingrowth sponges, dentures, ear drum plugs, synthetic cartilages, hemodialysis membranes and particulate carriers of tumor antibodies; and devices such as enzyme therapeutic systems, artificial organs and drug delivery systems.
  • the incorporation of the active principle in the gel can be achieved either by swelling the dry product in an aqueous solution containing the compound to be incorporated, or by mixing the active principle with the functionalized and purified polymer solution, and then by irradiating the same to obtain a gel.
  • This last method is particularly useful when large molecules are to be incorporated, such as peptides or proteins, which would be unlikely to penetrate a gel left to swell in an aqueous solution. It is, therefore, important to synthesize gels at low doses of gamma-irradiation, so as not to alter the biological activity of the incorporated drug.
  • EXAMPLE 2 1 gr of sodium alginate (medium viscosity) was dissolved in 20 ml of deionized distilled water (5% w/v) . To this solution was added 1.3 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 6.5 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v and the pH was 6.
  • Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator.
  • the purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) .
  • the minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 1.
  • the three-dimensional gels obtained from alginic acid were cut (1 cirr) and dried at ambient temperature for 24 hours and at a temperature of 60°C for 12 hours.
  • the samples, ' in threes were weighed dry, left to swell in deionized, distilled water until their equilibrium had been reached, and then weighed again in their completely swollen state.
  • the Q values relative to 1 and 8 hours of gamma-irradiation were 4.5-5.55 for 3% gels and 5.6-6.5 for 2.5% gels. The longer the gamma- irradiation time, the higher the Q value.
  • the purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) .
  • the minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 1.
  • the purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) .
  • the minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 1.
  • the three-dimensional gels obtained from alginic acid were cut (1 cirr) and dried at ambient temperature for 24 hours and at a temperature of 60°C for 12 hours.
  • the samples, in threes, were weighed dry, left to swell in deionized, distilled water until their equilibrium had been reached, and then weighed again in their completely swollen state.
  • the Q values relative to 1 and 8 hours of gamma-irradiation were 4.8-7.25 for 3% gels and 6.1-8.21 for 2.5% gels. The longer the gamma- irradiation time, the higher the Q value.
  • the purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) .
  • the minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 2.
  • Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator.
  • the purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) .
  • the minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 2.
  • the three-dimensional gels obtained from hyaluronic acid were cut (1 c ⁇ r) and dried at ambient temperature for 24 hours and at a temperature of 60°C for 12 hours.
  • the samples, in threes, were weighed dry, left to swell in deionized, distilled water until their equilibrium had been reached, and then weighed again in their completely swollen state.
  • the Q values relative to 1 and 8 hours of gamma-irradiation were 5.5-8.71 for 3% gels and 6.62-11.3 for 2% gels. The longer the gamma- irradiation time, the higher the Q value.
  • EXAMPLE 7 1 gr of the benzyl ester of hyaluronic acid, partially esterified (25%) , was dissolved in 20 ml of deionized, distilled water (5% w/v) . To this solution were added 0.8 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 4 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized, distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v and the pH was 6.
  • Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solutions to 1% in a rotor evaporator.
  • the purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) .
  • the minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 3.
  • Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator.
  • the purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) .
  • the minimum concentrations - necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 3.
  • the three-dimensional gels obtained from HA-25 were cut (1 c ⁇ r) and dried at ambient temperature for 24 hours and at a temperature of 60°C for 12 hours.
  • the samples, in threes, were weighed dry, left to swell in deionized, distilled water until their equilibrium had been reached, and then weighed again in their completely swollen state.
  • the Q values relative to 1 and 8 hours of gamma-irradiation were 4-5.62 for 2.5% gels and 4.6- 5.95 for 2% gels. The longer the gamma-irradiation time, the higher the Q value.

Abstract

A method for the synthesis for chemical gels or hydrogels from polyelectrolyte polysaccharides includes the steps of functionalizing the polyelectrolyte polysaccharide in order to introduce double bonds into the structure thereof; and subjecting the functionalized polysaccharide to gamma-irradiation in order to produce the hydrogel which constitutes a crosslinked structure. The produced hydrogel may be formed to be biocompatible and may be used as a slow release system for drugs.

Description

SYNTHESIS OF CHEMICAL GELS FROM POLYELECTROLYTE POLYSACCHARIDES BY GAMMA-IRRADIATION
OBJECT OF THE INVENTION The present invention is directed to a method for the synthesis of chemical gels or hydrogels by gamma- irradiation, starting with polyelectrolyte polysaccharides, such as alginic acid, hyaluronic acid and the esters thereof. The present invention is also directed to the chemical gel or hydrogel produced by this method. Gels synthesized by the described method can be used as slow release systems for drugs. FIELD OF THE INVENTION
Gels for pharmaceutical use are generally prepared from polymers by chemical means, such as by cross- linking the polymeric chain.
A method has previously been described in the literature, whereby it is possible to obtain chemical gels by gamma-irradiation, starting from water-soluble polymers such as dextran and gelatin ("Preparation and Characterization of Enzyme-Digestible Hydrogels from Natural Polymers by Gamma-irradiation", K. Kamath and K. Park, ACS Symposium Series, 545, 55-65, 1994) . According to the procedure described in the Kamath et al article, when polymers are functionalized with glycidyl acrylate to_ introduce double bonds into their polymeric structure, and exposed to gamma-irradiation, they give rise to chemical gels.
It has not yet been possible, however, to apply this method to polyelectrolyte polysaccharides. Indeed, it is well known that exposure to gamma-irradiation can lead to degradation of the polymeric chain with consequent loss of viscosity ("The radiation-induced degradation of hyaluronic acid", D. Deeble, G. 0'Phillips, E. Bothe, H. P. Schuchmann and C. von Sonntag, Radiat. Phvs. Chem.. vol. 37, N. 1, 115-118, 1991) .
SUMMARY OF THE INVENTION Accordingly, it is an object of the present invention to provide a method for synthesizing chemical gels from polyelectrolyte polysaccharides using gamma- irradiation.
It is another object of the present invention to provide a chemical gel . or hydrogel product which is biocompatible and which constitutes polyelectrolyte polysaccharide chains crosslinked using gamma- irradiation.
These and other objects of the present invention are fulfilled by providing a method for synthesizing biocompatible chemical gels or hydrogels which includes reacting polyelectrolyte polysaccharides with a functionalizing agent in order to introduce double bonds into the structure so as to produce functionalized polyelectrolyte polysaccharides; and subjecting the functionalized polyelectrolyte polysaccharides to gamma- irradiation in order to produce the chemical gels.
BRIEF DESCRIPTION OF DRAWINGS Figures 1, 2 and 3 show the conditions needed for the formation of gels from alginic acid, hyaluronic acid, and the 25% benzyl ester of hyaluronic acid.
Figure 1 is a graph showing the effect of the duration of gamma-irradiation and the effect of the concentration of sodium alginate on gel formation. Figure 2 is a graph showing the effect of the duration of gamma-irradiation and of the concentration of hyaluronic acid on gel formation.
Figure 3 is a graph showing the affect of the duration of gamma-irradiation and of the concentration of the 25% benzyl ester of hyaluronic acid (HA-25) on gel formation.
Figure 4 is a schematic diagram which shows in the upper portion a representation of the functionalization reaction between a polysaccharide (PS) with glycidyl acrylate; and in the lower portion a representation of the formation of one type of crosslinkage between two functionalized polysaccharides that are subjected to gamma-irradiation.
DETAILED DESCRIPTION OF THE INVENTION
The present invention has made it possible to synthesize chemical gels or hydrogels from polyelectrolyte polysaccharides using gamma-irradiation.
Polyelectrolyte polysaccharides are natural polymeric substances which contain ionic constituents.
Polyelectrolyte polysaccharides tend to swell when placed in water in order to minimize the repulsion between like positive or negative charges of the ionic constituents. These properties result in the so-called "polyelectrolyte" effect. Examples of polyelectrolyte polysaccharides include alginic acid, alginates, hyaluronic acid, hyaluronic acid esters including benzyl esters, polysialic acid, gellan, xanthane, welan, pectin, and glycosaminoglycans including condroitin sulphates, heparin sulphates, etc., as well as derivatives of these polysaccharides. These polyelectrolyte polysaccharides contrast with other natural polymeric substances, such as dextran and gelatin, which do not exhibit similar electrolytic properties and do not have the same chemical structure containing such ionic constituents.
The functionalization of polysaccharides with a functionalizing agent such as glycidyl acrylate in an aqueous medium and at ambient temperature causes double bonds to be introduced into the polymeric structure of the polysaccharides. Solutions of the polymers, purified with an excess of glycidyl acrylate by dialysis followed by gamma-irradiation, give rise to chemical gels. Indeed, because of the presence of double bonds and under the effect of the absorbed radiation, the functionalized polymers behave like macromolecules and like cross-linked products. Gels can, therefore, be formed without the addition of any outside cross-linking agents and the gels obtained do not need any further purification ("Preparation and Characterization of Enzyme-Digestible Hydrogels from Natural Polymers by Gamma-Irradiation", K. Kamath and K. Park, ACS Symposium Series, 545, 55-65, 1994) .
In order to accomplish the present invention, important changes have been made to the method of gel synthesis by gamma-irradiation as previously described for dextran and gelatin ("Preparation and Characterization of Enzyme-Digestible Hydrogels from Natural Polymers by Gamma-irradiation", K. Kamath and K. Park, ACS Symposium Series, 545, 55-65, 1994) . The method of the present invention provides for acidification of solutions of polyelectrolyte polysaccharides which have been functionalized with glycidyl acrylate, within a suitable pH range. Following irradiation, the acidified solutions give rise to the formation of gels at lower concentrations of polymers and for shorter irradiation times. In accordance with the present invention, the functionalization reaction for introducing double bonds into the polyelectrolyte polysaccharides involved the use of an appropriate functionalizing agent, such as glycidyl acrylate. As schematically illustrated in Figure 4, the upper reaction illustrates the reaction between glycidyl acrylate and the hydroxy group of a polyelectrolyte polysaccharides (i.e. "PS") . The reaction product results in the introduction of a double bond into the structure of the polyelectrolyte polysaccharide. This same reaction takes place between glycidyl acrylate and the carboxy groups of the polyelectrolyte polysaccharide. Figure 4 shows in the lower reaction scheme a simplified illustration of the functionalized polyelectrolyte polysaccharide containing a number "n" of double bonds which is subjected to gamma-irradiation in order to form one type of a crosslinked structure after the opening of the double bonds and the formation of radicals. The resulting crosslinks constitute aliphatic chains of a given length and result in the formation of gels having a three- dimensional structure which exhibits certain strength and resistance properties. Since not all of the carboxy groups of the polyelectrolyte polysaccharides are involved in the formation of ester bonds with the functionalizing agent, the resulting gels may be defined as polyelectrolytes having unique properties including a significant dependence on the pH and a significant dependence on the ionic strength of the aqueous medium in which the resulting gels are allowed to swell .
The method of synthesis of gels is conducted using solutions of polyelectrolyte polysaccharides at various concentrations. For example, the concentration range of 1-3% w/v may be used for alginic acid, hyaluronic acid and benzyl esters of hyaluronic acid with 25% esterification.
The solutions of polyelectrolyte polysaccharides may be functionalized using different quantities of an appropriate functionalizing agent such as glycidyl acrylate, for example in the range of 0.8-1.3 ml/1 g of polyelectrolyte polysaccharide.
Acidification of the polyelectrolyte polysaccharides in solution may be performed by the addition of a suitable acid, such as citric acid, hydrochloric acid or acetic acid, preferably without significantly altering the initial concentration of the polyelectrolyte polysaccharide. The polyelectrolyte polysaccharides are acidified in a pH range of from 1 to 6, more preferably a pH range of from 1 to 5, still more preferably of from 3 to 6, and most preferably between 2.5 and 3.5, before being subjected to gamma- irradiation. The acidification of the polyelectrolyte polysaccharide solution makes it possible to obtain gel formation at lower concentrations of the polymer and lower doses of irradiation. The polyelectrolyte polysaccharides are subjected to gamma-irradiation at a preferable dose range of from at least 0.01 to 0.5 Mrad, more preferably from 0.05 to 0.5 Mrad, and most preferably from about 0.0606 to 0.485 Mrad. The time periods during which the polyelectrolyte polysaccharides are subjected to gamma-irradiation is generally in the range of from 1 to 8 hours. For example, the gamma-irradiation dose may be 0.0606 Mrad/h for time intervals varying from about 1 to 8 hours. In addition to being subjected to gamma-irradiation after acidification, the polyelectrolyte polysaccharides may also be subjected to direct gamma-irradiation before acidification. It is preferable not to increase the irradiation dose above 0.5 Mrad because of the degradation effects that may occur. For example, the swelling ratio (Q) of the gels increases at doses of gamma-irradiation at 0.485 Mrad which suggests some degradation of the crosslinked structure of the gels. Also, if the produced gels are intended to be used in "drug delivery" systems, the use of lower doses of irradiation minimizes the possibility of damaging the biological activity of the active drug or principle incorporated into the gel.
The gels thus obtained swell when placed in water. Some of the synthesized gels described below were characterized by calculating their equilibrium swelling ratio (Q) , based on the weight of the dry gel and that which has swollen to equilibrium (W. S. W. Shalaby, K. Park , Pharm . Res . , 7 , 816 - 823 , 1990 ) .
It has been found that the formation of gels depends on the concentration of the polyelectrolyte polysaccharide, on the gamma-irradiation time, and on the degree of functionalization of the polyelectrolyte polysaccharide, this factor being directly linked with the quantity of glycidyl acrylate used during the functionalization reaction, and on the pH of the solution. Figures 1, 2 and 3 show the conditions needed for the formation of gels, in the case of alginic acid, hyaluronic acid and the 25% benzyl ester of hyaluronic acid (HA-25) , respectively. The lines in Figures 1-3 indicate the minimum concentration needed for the formation of three-dimensional gels at set gamma-- irradiation times. The areas above the lines represents the concentration conditions and irradiation times at which the formation of three-dimensional gels is possible. The areas below the lines represent the conditions in which the gels are not formed. Regarding the symbols in the Figures, Figure 1 shows the pH of the solution at pH=3(block symbol) and pH=6 (open symbol) ; and the quantity of glycidyl acrylate used to modify the alginate at 0.8 ml (circle) and 1.3 ml(square) . In Figure 2, the pH of the solution shown is pH=3 (square) and pH=6 (circle) . In Figure 3, the pH of the solutions shown are pH=3 (square) and pH=6(circle) . It has generally been found that by increasing the concentration of glycidyl acrylate and that of the polymer, it is possible to obtain the formation of gels after shorter exposure to gamma-irradiation. However, the longer the gamma-irradiation time, the greater the concentration of polymer necessary for the formation of a gel. This indicates a tendency for the polymers to degrade under the effects of irradiation.
On the other hand, it has been shown that the acidification of said polymer solutions leads to faster gel formation. When solutions of 1% sodium alginate w/v are acidified, they give rise to the formation of gels after only 1 hour of irradiation, while higher concentrations are necessary for solutions with pH=6 (2.5%) . The same results were found with low-molecular- weight hyaluronic acid and its 25% benzyl ester. The polysaccharides mentioned here are polyelectrolytes characterized by the presence of carboxy groups. Acidification of solutions of these polymers cause the formation of inter- and intra-chain hydrogen bonds and, consequently, the formation of stronger chemical gels following irradiation.
The acidification of such solutions before irradiation, therefore, allows the formation of gels with lower polymer concentrations and shorter irradiation times, thus avoiding possible degradation of the polymer. The gels synthesized according to the methods of the present invention can be used in the fields of medicine, health care, surgery and cosmetics, as well as in reconstructive and cosmetic surgery. For example, gels in the form of films or membranes can be used in various medical fields, such as in ophthalmology, dermatology, otorhinolaryngology and neurology, as tissue substitutes or organ coatings, as well as in tissue and organ transplants. Moreover, the gels can generally be used as a biocompatible material in cell cultures in three-dimensional systems, as well as in the form of fibers or threads for surgical suture, or in the form of gauzes for wound dressings. The gels of the present invention preferably include crosslinkage throughout the entire product such that all the polyelectrolyte molecules crosslink to form a single chemical entity.
Another important use for the compounds obtained by the method of synthesis of the present invention is as a controlled release system of one or more active principles, such as proteins, growth factors, enzymes, drugs or biologically active substances for oral, topical, s.c, i.m. or i.v. administration. Indeed, according to the dose of gamma-irradiation used, it is possible to obtain three-dimensional gels for use as drug release systems for topical or oral administration, or viscoelastic solutions in order to administer by the subcutaneous, intramuscular or intravenous routes. The biocompatible characteristics of the chemical gels or hydrogels of the present invention allows for their employment in potential and actual biomedical applications similar to those of conventional hydrogels, such as coatings for sutures, catheters, IUD's, blood detoxicants, electrode Sensors, vascular grafts, electrophoresis cells and cell culture substrates; homogeneous-type materials including electrophoresis gels, contact lenses, artificial corneas, vitreous humor replacements, estrous-inducers, breast or other soft tissue substitutes, burn dressings, bone ingrowth sponges, dentures, ear drum plugs, synthetic cartilages, hemodialysis membranes and particulate carriers of tumor antibodies; and devices such as enzyme therapeutic systems, artificial organs and drug delivery systems.
The incorporation of the active principle in the gel can be achieved either by swelling the dry product in an aqueous solution containing the compound to be incorporated, or by mixing the active principle with the functionalized and purified polymer solution, and then by irradiating the same to obtain a gel. This last method is particularly useful when large molecules are to be incorporated, such as peptides or proteins, which would be unlikely to penetrate a gel left to swell in an aqueous solution. It is, therefore, important to synthesize gels at low doses of gamma-irradiation, so as not to alter the biological activity of the incorporated drug. The possibility of obtaining gels with low doses of gamma-irradiation, as in the case of acidic solutions of the polyelectrolyte polysaccharides used in the present invention can, therefore, constitute an important advantage for the possible incorporation of drugs. Also, the release of the drug from the gel can be controlled by the rate of degradation of the polymeric matrix.
Below are some examples of the preparation of gels from polysaccharides according to the present invention.
EXAMPLE 1;
1 gr of sodium alginate (medium viscosity) was dissolved in 20 ml of deionized, distilled water (5% w/v) . To this solution was added 1.3 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 6.5 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized, distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v and the pH was 6. Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating to 1% in a rotating evaporator. The purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) . The minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 1.
EXAMPLE 2: 1 gr of sodium alginate (medium viscosity) was dissolved in 20 ml of deionized distilled water (5% w/v) . To this solution was added 1.3 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 6.5 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v and the pH was 6. Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator. The solutions, at varying concentrations were acidified to pH=3 by the addition of citric acid, so as to avoid any significant changes in the initial concentration of the polymer.
The purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) . The minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 1. The three-dimensional gels obtained from alginic acid were cut (1 cirr) and dried at ambient temperature for 24 hours and at a temperature of 60°C for 12 hours. The samples, ' in threes, were weighed dry, left to swell in deionized, distilled water until their equilibrium had been reached, and then weighed again in their completely swollen state. The Q values relative to 1 and 8 hours of gamma-irradiation were 4.5-5.55 for 3% gels and 5.6-6.5 for 2.5% gels. The longer the gamma- irradiation time, the higher the Q value.
EXAMPLE 3:
1 gr of sodium alginate (medium viscosity) was dissolved in 20 ml of deionized, distilled water (5% w/v). To this solution was added 0.8 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 4 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized, distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v and the pH was 6. Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator.
The purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) . The minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 1.
EXAMPLE 4:
1 gr of sodium alginate (medium viscosity) was dissolved in 20 ml of deionized, distilled water (5% w/v) . To this solution were added 0.8 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 4 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized, distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. After dialysis, the final concentration of the solution proved to be about 1% w/v and the pH was 6. Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator. Solutions at different concentrations were acidified to pH=3 by the addition of citric acid, in such a way as to avoid any significant changes from the initial concentration of the polymer.
The purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) . The minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 1.
The three-dimensional gels obtained from alginic acid were cut (1 cirr) and dried at ambient temperature for 24 hours and at a temperature of 60°C for 12 hours. The samples, in threes, were weighed dry, left to swell in deionized, distilled water until their equilibrium had been reached, and then weighed again in their completely swollen state. The Q values relative to 1 and 8 hours of gamma-irradiation were 4.8-7.25 for 3% gels and 6.1-8.21 for 2.5% gels. The longer the gamma- irradiation time, the higher the Q value.
EXAMPLE 5:
1 gr of hyaluronic acid was dissolved in 20 ml of deionized, distilled water (5% w/v) . To this solution was added 0.8 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 4 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized, distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v. Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator. The purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) . The minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 2.
EXAMPLE 6:
1 gr of hyaluronic acid was dissolved in 20 ml of deionized, distilled water (5% w/v) . To this solution was added 0.8 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 4 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized, distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v and the pH was 6. Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator. The solutions at different concentrations were acidified to pH=3 by the addition of citric acid, in such a way as to avoid any significant changes from the initial concentration of the polymer. The purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) . The minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 2.
The three-dimensional gels obtained from hyaluronic acid were cut (1 cπr) and dried at ambient temperature for 24 hours and at a temperature of 60°C for 12 hours. The samples, in threes, were weighed dry, left to swell in deionized, distilled water until their equilibrium had been reached, and then weighed again in their completely swollen state. The Q values relative to 1 and 8 hours of gamma-irradiation were 5.5-8.71 for 3% gels and 6.62-11.3 for 2% gels. The longer the gamma- irradiation time, the higher the Q value.
EXAMPLE 7: 1 gr of the benzyl ester of hyaluronic acid, partially esterified (25%) , was dissolved in 20 ml of deionized, distilled water (5% w/v) . To this solution were added 0.8 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 4 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized, distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v and the pH was 6. Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solutions to 1% in a rotor evaporator. The purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) . The minimum concentrations necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 3.
EXAMPLE 8:
1 gr of the benzyl ester of hyaluronic acid, partially esterified (25%) , was dissolved in 20 ml of deionized distilled water (5% w/v) . To this solution was added 0.8 ml of glycidyl acrylate. The reaction was performed at ambient temperature while stirring constantly. After 24 hours, the reaction was blocked by the addition of 4 ml of glycine at 20% w/v. The solution was then stirred for another 30 minutes, dialyzed for 48 hours in deionized distilled water and lastly centrifuged at 3,000 rpm for about 20 minutes. The final concentration of the solution proved to be about 1% w/v and the pH was 6. Solutions at concentrations of 1.5, 2, 2.5 and 3% were obtained by concentrating the solution to 1% in a rotor evaporator. The solutions at different concentrations were acidified to pH=3 by the addition of citric acid, in such a way as to avoid any significant changes from the initial concentration of the polymer. The purified solutions of functionalized polymer were then gamma-irradiated at a dose of 0.0606 Mrad/h for periods varying between 1 and 8 hours (0.0606-0.4848 Mrad) . The minimum concentrations - necessary for the formation of gels at the irradiation times indicated above are reported in Fig. 3.
The three-dimensional gels obtained from HA-25 were cut (1 cπr) and dried at ambient temperature for 24 hours and at a temperature of 60°C for 12 hours. The samples, in threes, were weighed dry, left to swell in deionized, distilled water until their equilibrium had been reached, and then weighed again in their completely swollen state. The Q values relative to 1 and 8 hours of gamma-irradiation were 4-5.62 for 2.5% gels and 4.6- 5.95 for 2% gels. The longer the gamma-irradiation time, the higher the Q value.
The invention being thus described, it is clear that these methods can be modified in various ways. Said modifications are not to be considered as divergences from the spirit and purpose of the invention and any modification which would be apparent to an expert in the field comes within the scope of the following claims.

Claims

CLAIMS 1. Process for the preparation of biocompatible hydrogels which includes the following steps: (a) reacting a polyelectrolyte polysaccharide with a functionalizing agent in order to introduce double bonds into the structure of the polysaccharide and produce a functionalized polysaccharide; (b) acidifying the functionalized polysaccharide of step (a) ; and (c) subjecting the acidified polysaccharide of step (b) to gamma-irradiation in order to form crosslinked bonds so as to produce the biocompatible hydrogel.
2. Process for the preparation of hydrogels according to claim 1, wherein the functionalizing agent is glycidyl acrylate which is present in an amount of between 0.8 and 1.
3 ml/1 g of the polyelectrolyte polysaccharide. 23 3. Process for the preparation of hydrogels according to claims 1 to 2, wherein the functionalized polysaccharide in step (b) is purified by dialysis.
4. Process for the preparation of hydrogels according to claims 1 to 3, wherein the gamma- irradiation is provided at a dose of 0.0606 to 0.485 Mrad.
5. Process for the preparation of hydrogels according to claims 1 to 4, wherein the functionalized polysaccharide is acidified in step (b) at a pH of between 3 and 6.
6. Process for the preparation of hydrogels according to claim 1, wherein the polyelectrolyte polysaccharide is alginic acid.
7. Process for the preparation of hydrogels according to claim 1, wherein the polyelectrolyte polysaccharide is hyaluronic acid.
8. Process for the preparation of hydrogels according to claim 1, wherein the polyelectrolyte polysaccharides are partially esterified benzyl esters of hyaluronic acid.
9. Biocompatible hydrogels produced according to claims 1 to 8 for the preparation of biomaterials for medical-surgical, pharmaceutical and cosmetic uses.
10. Three-dimensional biocompatible hydrogels produced according to claims 1 to 9 for the preparation of membranes, fibers, films, threads and gauzes.
11. Three-dimensional biocompatible hydrogels produced according to claims 1 to 10 for the preparation of controlled release systems for active principles such as proteins, growth factors, enzymes, drugs and biologically active substances for topical and oral uses.
12. Biocompatible hydrogels in the form of visco- elastic solutions according to claims 1 to 9 for the preparation of controlled release systems for active principles such as proteins, growth factors, enzymes, drugs and biologically active substances for topical, sub-cutaneous, intramuscular and intravenous uses.
13. Biocompatible hydrogel which comprises functionalized polyelectrolyte polysaccharide molecules crosslinked by exposure to gamma-irradiation.
14. Biocompatible hydrogel according to claim 13, which further comprises an active principle such as proteins, growth factors, enzymes, drugs and biologically active substances for topical, sub- cutaneous, intramuscular and intravenous uses.
15. Biocompatible hydrogel according to claims 13 to 14, wherein the swelling ratio Q value is from 4 to 11.3.
PCT/US1995/007224 1994-07-26 1995-06-07 Synthesis of chemical gels from polyelectrolyte polysaccharides by gamma-irradiation WO1996003147A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU28187/95A AU2818795A (en) 1994-07-26 1995-06-07 Synthesis of chemical gels from polyelectrolyte polysaccharides by gamma-irradiation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITPD94A000139 1994-07-26
IT94PD000139A IT1268718B1 (en) 1994-07-26 1994-07-26 SYNTHESIS OF CHEMICAL GEL FROM POLYSACCHARIDES POLYELECTROLYTES VIA GAMMA IRRADIATION

Publications (1)

Publication Number Publication Date
WO1996003147A1 true WO1996003147A1 (en) 1996-02-08

Family

ID=11390781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/007224 WO1996003147A1 (en) 1994-07-26 1995-06-07 Synthesis of chemical gels from polyelectrolyte polysaccharides by gamma-irradiation

Country Status (3)

Country Link
AU (1) AU2818795A (en)
IT (1) IT1268718B1 (en)
WO (1) WO1996003147A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842657A1 (en) * 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
WO1998022093A1 (en) * 1996-11-19 1998-05-28 Octoplus B.V. Process for the preparation of a controlled release system
WO2001048470A1 (en) * 1999-12-28 2001-07-05 Amersham Biosciences Ab The manufacture of improved support matrices
WO2002072862A2 (en) 2001-03-13 2002-09-19 Phillips Hydrocolloids Research Limited New biopolymers obtained by solid state irradiation in an unsaturated gaseous atmosphere
WO2003035716A1 (en) * 2001-10-25 2003-05-01 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
GB2401043A (en) * 2003-04-25 2004-11-03 Chisso Corp Degradable gels for the sustained delivery of pharmaceuticals
WO2005011772A2 (en) * 2003-07-31 2005-02-10 Scimed Life Systems, Inc. Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agents
US8105652B2 (en) 2002-10-24 2012-01-31 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
US9198875B2 (en) 2008-08-17 2015-12-01 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
US9393217B2 (en) 2007-06-14 2016-07-19 Massachusetts Institute Of Technology Self assembled films for protein and drug delivery applications
US9463244B2 (en) 2013-03-15 2016-10-11 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
US9737557B2 (en) 2013-02-26 2017-08-22 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
US10278927B2 (en) 2012-04-23 2019-05-07 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
US11419947B2 (en) 2017-10-30 2022-08-23 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826678A (en) * 1972-06-06 1974-07-30 Atomic Energy Commission Method for preparation of biocompatible and biofunctional materials and product thereof
US4321117A (en) * 1978-03-09 1982-03-23 Japan Atomic Energy Research Institute Process for preparing a polymer composition
WO1982002716A1 (en) * 1981-02-09 1982-08-19 Patent Dev Corp Nat Modified synthetic hydrogels
EP0174849A2 (en) * 1984-09-11 1986-03-19 The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Hydrogel materials
GB2222081A (en) * 1988-07-20 1990-02-28 Univ Salford Business Services Sterilising pharmaceutical formulations
WO1992003172A1 (en) * 1990-08-17 1992-03-05 Sebapharma Gmbh & Co. Dressing system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826678A (en) * 1972-06-06 1974-07-30 Atomic Energy Commission Method for preparation of biocompatible and biofunctional materials and product thereof
US4321117A (en) * 1978-03-09 1982-03-23 Japan Atomic Energy Research Institute Process for preparing a polymer composition
WO1982002716A1 (en) * 1981-02-09 1982-08-19 Patent Dev Corp Nat Modified synthetic hydrogels
EP0174849A2 (en) * 1984-09-11 1986-03-19 The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Hydrogel materials
GB2222081A (en) * 1988-07-20 1990-02-28 Univ Salford Business Services Sterilising pharmaceutical formulations
WO1992003172A1 (en) * 1990-08-17 1992-03-05 Sebapharma Gmbh & Co. Dressing system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. BARTHOLOME et al. "Ullmanns EnzyklopÛdie der technischen Chemie", 4th edition, vol. 22, published 1982 by Verlag Chemie, Weinheim pages 198-199, especially page 198, left column, line 16 - page 199, left column; 8th line after fig. 41. *
K.R. KAMATH et al. "Preparation and Character- ization of Enzyme-Digestible Hydrogels from Natural Poly- mers by Gamma Irradiation", 204th National Meeting of the ACS, ACS Symposium 1992, cited in ACS Symposium Series 545, American Chemical Society, Washington, DC, 1994, pages 55-65, especially page 55; abstract; page 56, line 15 - page 57, line 16; page 58, lines 12-23; page 61, line after fig. 5 - page 63, last line (cited in the application). *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022093A1 (en) * 1996-11-19 1998-05-28 Octoplus B.V. Process for the preparation of a controlled release system
EP0842657A1 (en) * 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
WO2001048470A1 (en) * 1999-12-28 2001-07-05 Amersham Biosciences Ab The manufacture of improved support matrices
US7208532B2 (en) 1999-12-28 2007-04-24 Ge Healthcare Bio-Sciences Ab Manufacture of improved support matrices
WO2002072862A2 (en) 2001-03-13 2002-09-19 Phillips Hydrocolloids Research Limited New biopolymers obtained by solid state irradiation in an unsaturated gaseous atmosphere
JP2004536624A (en) * 2001-03-13 2004-12-09 フィリップス ハイドロコロイド リサーチ リミテッド Novel biopolymer obtained by solid state irradiation in unsaturated gas atmosphere
EP1565483A4 (en) * 2001-03-13 2008-03-05 San Ei Gen Ffi Inc New biopolymers obtained by solid state irradiation in an unsaturated gaseous atmosphere
EP1565483A2 (en) * 2001-03-13 2005-08-24 San-Ei Gen F.F.I., Inc. New biopolymers obtained by solid state irradiation in an unsaturated gaseous atmosphere
US7112361B2 (en) 2001-10-25 2006-09-26 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
WO2003035716A1 (en) * 2001-10-25 2003-05-01 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
US8105652B2 (en) 2002-10-24 2012-01-31 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
GB2401043B (en) * 2003-04-25 2007-10-17 Chisso Corp Drug
GB2401043A (en) * 2003-04-25 2004-11-03 Chisso Corp Degradable gels for the sustained delivery of pharmaceuticals
WO2005011772A3 (en) * 2003-07-31 2005-04-14 Scimed Life Systems Inc Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agents
WO2005011772A2 (en) * 2003-07-31 2005-02-10 Scimed Life Systems, Inc. Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agents
US7914805B2 (en) 2003-07-31 2011-03-29 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agent
US9393217B2 (en) 2007-06-14 2016-07-19 Massachusetts Institute Of Technology Self assembled films for protein and drug delivery applications
US9198875B2 (en) 2008-08-17 2015-12-01 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
US10278927B2 (en) 2012-04-23 2019-05-07 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
US9737557B2 (en) 2013-02-26 2017-08-22 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
US9463244B2 (en) 2013-03-15 2016-10-11 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
US11419947B2 (en) 2017-10-30 2022-08-23 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment

Also Published As

Publication number Publication date
AU2818795A (en) 1996-02-22
ITPD940139A0 (en) 1994-07-26
IT1268718B1 (en) 1997-03-06
ITPD940139A1 (en) 1996-01-26

Similar Documents

Publication Publication Date Title
EP0296078B1 (en) Biomaterials based on mixtures of collagen, chitosan and glycosaminoglycans, method for preparing them and their use in human medicine
US10265436B2 (en) Immobilized bioactive hydrogel matrices as surface coatings
JP4214051B2 (en) Elastin crosslinked body and method for producing the same
US5324775A (en) Biologically inert, biocompatible-polymer conjugates
JP4458852B2 (en) Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
EP0200574B1 (en) A biomaterial comprising a composite material of chitosan derivative and collagen and a process for the production of the same
US6586493B1 (en) Polysaccharide-based hydrogels and pre-gel blends for the same
CN109734825B (en) Process for making shaped cross-linked hyaluronic acid products
CN106822183B (en) Photosensitive platelet-rich plasma gel and preparation method and application thereof
US20020049281A1 (en) Process for cross-linking hyaluronic acid to polymers
WO1990012564A1 (en) Glucan/collagen therapeutic eye shields
EP0648239A1 (en) Biocompatible polymer conjugates
FR2889449A1 (en) Implantable preparation, useful e.g. for healing, protecting or filling skin and surgical wounds, comprises it is prepared from a globin chemically modified to be at least partly soluble at physiological pH
WO1996003147A1 (en) Synthesis of chemical gels from polyelectrolyte polysaccharides by gamma-irradiation
CN115400260B (en) Repairing gel containing recombinant humanized collagen and preparation method thereof
CN110624103A (en) Biomaterial device and topical composition for the treatment of skin disorders
CN113599507A (en) Preparation method of glucose-triggered active oxygen response injection type composite hydrogel
CN111012803A (en) Biomaterial device and topical composition for guided tissue regeneration
Sionkowska 11 Natural Polymers as
Sionkowska Natural Polymers as Components of Blends for Biomedical Applications
CN114452436B (en) Collagen-based injectable self-repairing hydrogel and preparation method thereof
EP3882279A1 (en) Genipin-crosslinked pdrn-sacran biopolymer scaffolds
JPH0622580B2 (en) Medical material composed of succinyl chitosan
Sionkowska 11 NC atural Polymers as omponents of Blends
JPH0567300B2 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase